Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
about
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerMarkers of resistance to anti-EGFR therapy in colorectal cancerPatient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic reviewThe Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal CancerTreatment Individualization in Colorectal CancerDual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal CancersMolecular phenotypes of colorectal cancer and potential clinical applicationsUsing large-scale genomics data to identify driver mutations in lung cancer: methods and challengesPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesDual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancerPhase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerMiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting BimCrossHub: a tool for multi-way analysis of The Cancer Genome Atlas (TCGA) in the context of gene expression regulation mechanismsSynergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cellsSystematic identification of combinatorial drivers and targets in cancer cell linesDiscovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical ModelingClinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model.Patient-derived xenograft models: an emerging platform for translational cancer researchmTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer.mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma.Molecular markers predictive of chemotherapy response in colorectal cancerPhosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948.Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells.Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer.miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signallingLenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activitySuperior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesMEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.Mitochondrial clearance by the STK38 kinase supports oncogenic Ras-induced cell transformation.Network analysis of differential Ras isoform mutation effects on intestinal epithelial responses to TNF-α.PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.
P2860
Q24563539-86836867-50C7-4C32-B105-E0D83F747B34Q24598640-07E15F59-DDCE-4169-9D13-1846A6A3D890Q26741651-4C6A64E6-214F-4DCE-9717-E3F0E367E792Q26744721-3FF0EF00-84ED-475B-8772-25373B233950Q26776215-741FB7F8-5622-4ACA-ADCD-D796E1D0866CQ26781362-57D438F2-F8E9-4E5E-ADE2-D52447CE6C1EQ26785725-B3CD419A-3AFC-472D-A6F3-592443008052Q26800833-0977E6E7-B7E7-4A3B-9157-850CDBC3284DQ27015224-2DC8E004-EE93-4079-AA7D-6060C94F83DDQ27324821-9781479B-17DF-4717-8F20-F0379BA52302Q27853084-54A1811D-4114-4032-83B1-758610A0FB2BQ27853184-9F71689B-5BE2-4BD5-AC5F-6001FBC401D9Q27853284-9464685A-2A83-4320-A9A3-5FC43BF1DA25Q28076490-CBD2647C-504C-4230-8D17-8ED020ABF854Q28118859-1CF6F743-7B4D-46A7-84DF-9D47675624CCQ28392625-3DCD7787-5B7B-4E1D-91CB-170856ED5499Q28485464-D95A7BD4-7FEC-46BC-B06C-95032A4C5A81Q28486051-45DE83BF-C09D-4A51-A7B7-3D77702F4117Q28547862-5863B8B3-B970-4F3F-A92E-4CE5B6BAE292Q33767369-E6C4F9B6-99DC-483A-9720-AF6DFE34E438Q34205518-06F93B2C-A63B-4BFE-BED7-A248C00CDD6DQ34673900-27422032-64CA-4C70-8962-DD5BD98B5311Q35161368-8DD820DE-6B3B-4CFC-93D9-6FC820E62AADQ35236736-5469C4BE-A0A7-43CB-B45B-2335C9644E4AQ35761956-05CE59D2-A53C-44DB-A28F-7BCAABAA3985Q36093388-2BEB795A-DE0A-452A-B6E1-418861A16B55Q36171262-9791EE0D-D7B5-47F7-83EF-1B0A55FA29B6Q36471372-58377FB7-BD4F-45F1-990C-CCCC351490CEQ36546669-CE9FC6D9-4176-41AC-A229-E821FB72639AQ36814884-F1968560-D4B1-4D8F-A764-97DAA0509F7AQ36871777-DB503CC4-BB24-47B6-9DC3-AD8E188DEC69Q37030911-98AF5287-64E1-4654-A6D5-9F394A6AB25FQ37058831-3FD8D857-DBDC-46B8-A3A8-DE2EAED89D53Q37381179-334D4588-6357-40AA-82BD-2C5A6EABDFABQ37457602-7722C5E2-CB44-4AD4-A56A-4D522F1B1BDDQ37536691-AC2E9021-5662-4370-A4DB-5D536FDCF1BAQ37536809-CCBCFE0C-95EA-4A50-8954-070B77C49A34Q37666240-44DF6373-09A5-4B99-952D-A157C5E42445Q38084846-2D57817F-9EEF-40E3-A4FB-59A31A776682Q38148747-27D97CAE-32CE-45E1-AC1B-5065AF3F081E
P2860
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Inhibition of MEK and PI3K/mTO ...... -mutant colorectal carcinomas.
@en
Inhibition of MEK and PI3K/mTO ...... -mutant colorectal carcinomas.
@nl
type
label
Inhibition of MEK and PI3K/mTO ...... -mutant colorectal carcinomas.
@en
Inhibition of MEK and PI3K/mTO ...... -mutant colorectal carcinomas.
@nl
prefLabel
Inhibition of MEK and PI3K/mTO ...... -mutant colorectal carcinomas.
@en
Inhibition of MEK and PI3K/mTO ...... -mutant colorectal carcinomas.
@nl
P2093
P50
P1476
Inhibition of MEK and PI3K/mTO ...... -mutant colorectal carcinomas.
@en
P2093
Alberto Pisacane
Andrea Muratore
Dario Ribero
Davide Torti
Eugenia R Zanella
Francesco Galimi
Francesco Sassi
Giorgia Migliardi
Livio Trusolino
Lorenzo Capussotti
P304
P356
10.1158/1078-0432.CCR-11-2683
P407
P577
2012-03-05T00:00:00Z